Bioregulator Peptides Guide: Vilon, Pinealon, Vesugen, Testagen, Prostamax and Thymalin
Bioregulator peptides are the shortest things on a research shelf. Two, three or four amino acids. Names that sound like small towns. They all trace back to one research tradition in St. Petersburg, and they all share a big, open question: do peptides this short do anything specific at all? This bioregulator peptides guide lines them up from shortest to longest, says where each came from, and sets out what the literature covers and what it does not.
Where bioregulator peptides came from
Over several decades, researchers at what became the St. Petersburg Institute of Bioregulation and Gerontology worked with extracts from animal organs: thymus, pineal gland, blood vessels, prostate. Later, the group led by Vladimir Khavinson designed very short synthetic peptides based on the amino acid composition of those extracts. Each short peptide was paired with a tissue, and each got a trade-style name. The group calls them peptide bioregulators. Online you will also see "Khavinson peptides".
The working idea is that a short peptide can enter a cell, reach the nucleus and change which genes are read. The group has published docking models and some binding experiments to support this. It remains a hypothesis, and the authors themselves say so in several papers. Keep that in mind as you read each entry below.
Vilon (Lys-Glu)
The shortest of the set. Vilon is the dipeptide Lys-Glu, written KE. It is also described as one of the active components of Thymalin, the thymus extract at the end of this list.
What the literature covers. Khavinson et al., 2002 reported stimulation of thymocyte proliferation and sphingomyelinase activity in mouse cells. Khavinson et al., 2000 followed female CBA mice for lifespan and spontaneous tumours. Lezhava et al., 2004 described loosening of condensed chromatin in cultured lymphocytes from older people. Avolio et al., 2022 found lower TNF and IL-6 expression in a monocyte-derived cell line after lipopolysaccharide exposure, with Vilon showing only a small effect on ERK1/2 phosphorylation compared with the other peptides tested.
Limits. The mouse lifespan result is a single-group animal finding. Human reports are small Russian-language studies, for example in patients with diabetes, and the abstracts give no sample sizes. The DNA-binding idea rests mainly on molecular modelling. No registered trial or FDA-approved product was found.
Pinealon (Glu-Asp-Arg)
Pinealon is the tripeptide Glu-Asp-Arg, or EDR. Its name points to the pineal gland, and most of its studies are about neurons.
What the literature covers. Khavinson et al., 2011 reported lower accumulation of reactive oxygen species, less necrotic cell death and delayed ERK 1/2 activation in cultured cells, including cerebellar granule cells and PC12 cells. Arutjunyan et al., 2012 studied offspring of rats with methionine-induced hyperhomocysteinemia. Khavinson et al., 2020 reviewed Alzheimer's disease cell models and proposed that the peptide enters cells and binds histones or nucleic acids. The review itself words this as an assumption.
Limits. Almost all of the work is from one research group. Human reports are small and appear mainly in Russian-language journals; Meshchaninov et al., 2015 is one example, with 32 people given either Vesugen or Pinealon. No trials were found on ClinicalTrials.gov.
Vesugen (Lys-Glu-Asp)
Vesugen is the tripeptide Lys-Glu-Asp, or KED. The group describes it as a vascular peptide, though much of the recent work is on neurons.
What the literature covers. Vascular endothelial cell cultures, with changes in the proliferation marker Ki-67. Neuronal differentiation of stem cells, with changes in nestin and GAP43. Khavinson et al., 2021 looked at an Alzheimer's disease cell model. Khavinson et al., 2012 studied aging cultured fibroblasts. The most careful recent paper is Kraskovskaya et al., 2024: in neurons induced from fibroblasts, the short peptides increased dendrite branching but had no effect on mitochondria, lysosomes or the p16 protein. That is a useful negative result, and it comes from the same network.
Limits. Human data are limited to small Russian-language studies, including a before-and-after study of 41 patients reported by Kitachev et al., 2014. The proposed binding to gene promoters rests largely on computer docking. No registered trial or FDA-approved product was found.
Testagen (Lys-Glu-Asp-Gly)
Testagen is the name used in some papers for the tetrapeptide Lys-Glu-Asp-Gly, or KEDG. Other papers on the same sequence say it was designed from the amino acid composition of anterior pituitary extracts, and do not use the name Testagen at all.
What the literature covers. Fedoreyeva et al., 2011 tracked fluorescently labelled peptide into the cytoplasm, nucleus and nucleolus of HeLa cells and showed sequence-dependent binding to short DNA fragments in a test tube. Kuznik et al., 2008 studied thyroid structure and function in neonatally hypophysectomized chickens. Khavinson et al., 2020 list KEDG among peptides reported to stimulate immune cell differentiation.
Limits. Despite the name, none of the sources we opened describe work on testicular tissue. There is no human study of this peptide in those sources either. The literature is very small: cells, test tubes and birds. Treat it as an early research compound and nothing more.
Prostamax (Lys-Glu-Asp-Pro)
Prostamax is the tetrapeptide Lys-Glu-Asp-Pro, or KEDP. The St. Petersburg group describes KEDP as a regulator of prostate function; the name-to-sequence pairing comes from a single 2012 paper.
What the literature covers. Khavinson et al., 2004 tested Prostamax alongside Vilon, Epitalon and others on cultured leukocytes from donors aged 75 to 88, reporting decondensation of densely packed chromatin and activation of ribosomal genes. Dzhokhadze et al., 2012 reported similar chromatin changes. Zakutskii et al., 2006 used prostate explants from young and old rats. Khavinson et al., 2023 ran computer docking suggesting KEDP could bind LAT and PEPT1 transporters.
Limits. PubMed returns about six records under this name, several in Russian. The docking result has not been confirmed by experiment in the sources opened. No human trials were found.
Thymalin (a thymus extract, not a single peptide)
Thymalin breaks the pattern. It is not one defined sequence. It is a polypeptide complex extracted from calf thymus, with components up to about 10 kDa. The dipeptides Lys-Glu (Vilon) and Glu-Trp are described as its active constituents.
What the literature covers. Khavinson et al., 2020 reported that Thymalin lowered the stem-cell markers CD44 and CD117 and raised CD28 on human hematopoietic stem cells in culture, which the authors read as a shift toward mature T lymphocytes. Linkova et al., 2023 found lower IL-1beta, IL-6 and TNF-alpha production in human blood mononuclear cells after lipopolysaccharide exposure. Khavinson et al., 2021 describes a single-center, open-label trial of Thymalin as an add-on to standard treatment in 92 patients with COVID-19.
Limits. One source states that Thymalin has been approved for medical use in Russia as an immunomodulator since 1982. That describes a registered Russian product, not research-grade material. The developers themselves write that the molecular mechanism requires further study. The COVID-19 trial was small and open-label. No FDA label or ClinicalTrials.gov record was found.
Reading this literature well
Four patterns run through all six entries. Knowing them makes you a better reader.
- One group. Most papers come from the St. Petersburg institute and its collaborators in Tbilisi, Chita and Italy. Independent replication is thin.
- Russian-language reports. Many human reports exist only as Russian abstracts, often without sample sizes or blinding described.
- Cells and tissue, not people. The best-documented findings are in cultured cells, explants and small animals.
- Mechanism by modelling. The gene-binding idea is supported mostly by docking calculations and a few binding assays. It is a hypothesis.
None of this is a reason to ignore the field. It is a reason to design experiments that could confirm or refute it.
Testing very short peptides
A dipeptide or tripeptide is small enough that identity and purity testing differ from a long peptide. Mass spectrometry confirms the exact mass, which for a two- or three-residue peptide is unambiguous. HPLC separates the main peak from leftovers of synthesis. Each lot's certificate states its measured purity and identity. For Thymalin the picture is different: as an extract it has no single mass, so documentation describes the preparation and its testing rather than one peak.
The shelf, side by side
| Name | Sequence | Length | Research stage (as the literature reports it) |
|---|---|---|---|
| Vilon | Lys-Glu (KE) | 2 | Mainly preclinical; small Russian human studies |
| Pinealon | Glu-Asp-Arg (EDR) | 3 | Mainly preclinical; small Russian human studies |
| Vesugen | Lys-Glu-Asp (KED) | 3 | Mainly preclinical; small Russian human studies |
| Testagen | Lys-Glu-Asp-Gly (KEDG) | 4 | Preclinical; very small literature |
| Prostamax | Lys-Glu-Asp-Pro (KEDP) | 4 | Preclinical; very small literature |
| Thymalin | Extract (KE and EW active) | Mixed, up to about 10 kDa | Registered drug in Russia; no FDA approval found |
All six come as lyophilised powder in 20 mg crimp-sealed glass vials, stored at -20 °C, desiccated. House codes run PTY-VILN-20, PTY-PIN-20, PTY-VESU-20, PTY-TEST-20, PTY-PROS-20 and PTY-THYM-20. Product pages: Thymalin, Prostamax and Testagen.
Frequently asked questions
What makes a peptide a "bioregulator"?
The label comes from the research group, not from chemistry. It describes very short synthetic peptides designed from organ extracts and paired with a tissue. There is no separate chemical class; a bioregulator is simply a short peptide with a hypothesis attached.
Is Vilon part of Thymalin?
Yes, in the sense that Lys-Glu (Vilon) and Glu-Trp are described as the active constituents of the Thymalin extract. Thymalin itself is a mixture with components up to about 10 kDa, so it is not simply Vilon in a different vial.
Which of these has the most published research?
Thymalin by a wide margin, with several hundred PubMed records, most in Russian. Prostamax has about six. The others sit in between, with a few dozen records each, largely from one group.
Do any bioregulator peptides have FDA approval?
None that we found. Thymalin is reported by its developers as a registered immunomodulator in Russia since 1982. That describes a Russian pharmaceutical product, not research-grade material, and no FDA label exists for any of the six.
See it in the catalogue: Thymalin.
For laboratory research use only. Products sold by Amino Party Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.